Drugs / GS-0151
last change May 2025 re-read 3 minutes ago

GS-0151

Developed for
rheumatoid arthritis
Investigated by
Gilead Sciences

Trials 1

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06902519 May 2025 → Mar 2027 expected rheumatoid arthritis Gilead Sciences Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GS-0151 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06902519 ↗